Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 92

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 92
---
 about our business and the industry in
which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of
our forward-looking statements in this prospectus may turn out to be inaccurate. Important factors that may cause actual results to differ
materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this
prospectus. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements.

The forward-looking statements
included in this prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances
reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update
or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however,
review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus.
See “Where You Can Find More Information.”

<div align='center'>57

USE OF PROCEEDS</div>

We expect to receive approximately
$9.1 million in net proceeds from the sale of Ordinary Shares offered by us in this offering (approximately $10.6 million
if the Representative’s exercises its over-allotment option in full), based upon an assumed public offering price of $11.00 per
Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting
discounts and commissions and estimated offering expenses payable by us.

Each $0.25 increase or decrease
in the assumed initial public offering price of $11.00 per Ordinary Share, which is the midpoint of the price range set forth on
the cover page of this prospectus, would increase (decrease), the net proceeds to us from this offering by $0.23 million, assuming the
number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of Ordinary